Immune-Boosting drug may help women with repeated IVF failure
NCT ID NCT07675980
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether Thymosin-α1, an immune-modulating drug, can increase the chance of live birth in women aged 18-40 who have had at least two failed embryo transfers with genetically normal embryos. Participants receive either the drug or a placebo during their IVF cycle and continue until about 11 weeks of pregnancy. The study aims to see if calming the immune system helps the embryo implant and grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Thymosin-α1
- What this could lead to
- If it works, this could offer a new treatment option for women who have repeatedly failed to achieve pregnancy despite using genetically normal embryos.
- What could go wrong
- This is a mid-stage trial with 136 participants, so results may not apply to all women. The drug may not improve live birth rates and could have side effects like injection site reactions or immune effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT IMPLANTATION FALIURE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fakih IVF
RECRUITINGAbu Dhabi, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.